MA37809A1 - Administration de médicament biodégradable pour compositions hydrophobes - Google Patents
Administration de médicament biodégradable pour compositions hydrophobesInfo
- Publication number
- MA37809A1 MA37809A1 MA37809A MA37809A MA37809A1 MA 37809 A1 MA37809 A1 MA 37809A1 MA 37809 A MA37809 A MA 37809A MA 37809 A MA37809 A MA 37809A MA 37809 A1 MA37809 A1 MA 37809A1
- Authority
- MA
- Morocco
- Prior art keywords
- drug delivery
- biodegradable drug
- hydrophobic compositions
- polyester
- polyethylene glycol
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title abstract 2
- 230000002209 hydrophobic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 229920000728 polyester Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 229960003150 bupivacaine Drugs 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 229920000359 diblock copolymer Polymers 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 abstract 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229920000428 triblock copolymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des compositions pour l'administration de médicament biodégradable comprenant un copolymère tribloc contenant un polyester et un polyéthylèneglycol et un copolymère dibloc contenant un polyester et un polyéthylèneglycol à coiffe terminale, ainsi qu'au moins une substance pharmaceutiquement active ou substance active hydrophobe telle que l'acétate de médroxyprogestérone, le lévonorgestrel, la cyclosporine, la progestérone ou la bupivacaïne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665192P | 2012-06-27 | 2012-06-27 | |
| PCT/IB2013/001547 WO2014001904A1 (fr) | 2012-06-27 | 2013-06-27 | Administration de médicament biodégradable pour compositions hydrophobes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37809A1 true MA37809A1 (fr) | 2017-07-31 |
| MA37809B1 MA37809B1 (fr) | 2018-12-31 |
Family
ID=49117888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37809A MA37809B1 (fr) | 2012-06-27 | 2013-06-27 | Administration de médicament biodégradable pour compositions hydrophobes |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20150150987A1 (fr) |
| EP (1) | EP2866837B1 (fr) |
| JP (1) | JP6134788B2 (fr) |
| KR (1) | KR102189442B1 (fr) |
| CN (1) | CN104582733B (fr) |
| AU (1) | AU2013282891B2 (fr) |
| BR (1) | BR112014031773B1 (fr) |
| CA (1) | CA2877083C (fr) |
| CL (1) | CL2014003531A1 (fr) |
| CO (1) | CO7160098A2 (fr) |
| CR (1) | CR20140581A (fr) |
| CU (1) | CU24287B1 (fr) |
| EA (1) | EA031522B1 (fr) |
| ES (1) | ES2938586T3 (fr) |
| IL (1) | IL236472B (fr) |
| IN (1) | IN2014DN11063A (fr) |
| MA (1) | MA37809B1 (fr) |
| MX (1) | MX353280B (fr) |
| SG (1) | SG11201408658PA (fr) |
| TN (1) | TN2014000520A1 (fr) |
| UA (1) | UA113549C2 (fr) |
| WO (2) | WO2014001904A1 (fr) |
| ZA (1) | ZA201409291B (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP6640725B2 (ja) | 2014-01-27 | 2020-02-05 | セントレ ナショナル デ ラ レチャーチェ シャーティフィック | ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3169315B1 (fr) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
| US20170290846A1 (en) * | 2014-09-30 | 2017-10-12 | University Of Tennessee Research Foundation | In situ gelling form for long-acting drug delivery |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| FR3027522B1 (fr) | 2014-10-27 | 2016-12-09 | I Ceram | Composition poreuse chargee en principe actif |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| EP4374861A3 (fr) | 2015-11-16 | 2024-08-07 | MedinCell S.A. | Procédé de morcellement et/ou de ciblage de principes pharmaceutiquement actifs vers un tissu synovial |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11766400B2 (en) * | 2016-10-24 | 2023-09-26 | Yale University | Biodegradable contraceptive implants |
| CA3057438A1 (fr) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Formulations d'olanzapine a liberation prolongee |
| ES3015765T3 (en) * | 2017-07-17 | 2025-05-07 | Medincell S A | Pharmaceutical composition |
| GB2568526A (en) | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
| CN108078911A (zh) * | 2017-12-08 | 2018-05-29 | 复旦大学 | 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法 |
| ES2990218T3 (es) * | 2018-08-22 | 2024-11-29 | Bacainn Biotherapeutics Ltd | Composiciones de ciclosporina y métodos de uso |
| GB201900258D0 (en) * | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
| ES3058225T3 (en) | 2019-09-13 | 2026-03-09 | Medincell S A | Drug delivery formulations |
| CN111700876A (zh) * | 2020-03-12 | 2020-09-25 | 上海市肿瘤研究所 | 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法 |
| EP4262749A1 (fr) | 2020-12-16 | 2023-10-25 | Medincell S.A. | Méthodes et compositions pour le traitement prophylactique du virus sars-cov-2 (covid-19) |
| FI20215186A1 (en) | 2021-02-19 | 2022-08-20 | Rebio Tech Oy | Compositions for ophthalmic treatment |
| BR112023018652A2 (pt) | 2021-03-17 | 2023-10-03 | Medincell S A | Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis |
| KR20240006032A (ko) * | 2021-04-30 | 2024-01-12 | 메딘셀 에스.에이. | 새로운 제형 |
| WO2025081046A1 (fr) * | 2023-10-11 | 2025-04-17 | The Brigham And Women's Hospital, Inc. | Suspension injectable de médicaments hydrophobes à très forte charge destinée à une administration de médicament à long terme |
| WO2026013080A1 (fr) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Composition pharmaceutique à base de polymères biodégradables comprenant de la polyoxazoline |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| WO2002085337A1 (fr) | 2001-04-20 | 2002-10-31 | The University Of British Columbia | Systemes d'administration de medicament micellaire pour medicaments hydrophobes |
| CN100408099C (zh) * | 2000-11-09 | 2008-08-06 | 阿斯特拉曾尼卡有限公司 | 含有嵌段共聚物的口服药物组合物 |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| US6592899B2 (en) * | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| PT1638535E (pt) * | 2003-06-26 | 2007-11-08 | Mediolanum Pharmaceuticals Ltd | Implantes subcutâneos com libertação inicial de princípio activo limitada e subsequente sua libertação extensiva com variação linear |
| US20050112170A1 (en) * | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
| AU2006278328A1 (en) * | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
| CN101273963A (zh) * | 2007-11-22 | 2008-10-01 | 山东蓝金生物工程有限公司 | 一种含激素类抗癌药的温控缓释注射剂 |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| WO2010059001A2 (fr) * | 2008-11-21 | 2010-05-27 | 주식회사 삼양사 | Composition de micelles polymères pour le traitement de cellules cancéreuses résistantes |
| CN101810560B (zh) * | 2009-02-20 | 2013-07-10 | 北京大学 | 环孢a聚合物胶束组合物 |
| MX347090B (es) * | 2010-12-29 | 2017-04-11 | Medincell | Composiciones de suministro de farmacos biodegradables. |
-
2013
- 2013-06-27 JP JP2015519379A patent/JP6134788B2/ja active Active
- 2013-06-27 CA CA2877083A patent/CA2877083C/fr active Active
- 2013-06-27 IN IN11063DEN2014 patent/IN2014DN11063A/en unknown
- 2013-06-27 AU AU2013282891A patent/AU2013282891B2/en active Active
- 2013-06-27 WO PCT/IB2013/001547 patent/WO2014001904A1/fr not_active Ceased
- 2013-06-27 EP EP13758976.8A patent/EP2866837B1/fr active Active
- 2013-06-27 KR KR1020157002309A patent/KR102189442B1/ko active Active
- 2013-06-27 CU CUP2014000148A patent/CU24287B1/xx unknown
- 2013-06-27 ES ES13758976T patent/ES2938586T3/es active Active
- 2013-06-27 EA EA201492172A patent/EA031522B1/ru not_active IP Right Cessation
- 2013-06-27 US US14/410,994 patent/US20150150987A1/en not_active Abandoned
- 2013-06-27 SG SG11201408658PA patent/SG11201408658PA/en unknown
- 2013-06-27 MA MA37809A patent/MA37809B1/fr unknown
- 2013-06-27 BR BR112014031773-9A patent/BR112014031773B1/pt active IP Right Grant
- 2013-06-27 MX MX2014015902A patent/MX353280B/es active IP Right Grant
- 2013-06-27 CN CN201380044335.7A patent/CN104582733B/zh active Active
- 2013-06-27 WO PCT/IB2013/001549 patent/WO2014001905A1/fr not_active Ceased
- 2013-06-27 UA UAA201413827A patent/UA113549C2/uk unknown
-
2014
- 2014-12-15 TN TN2014000520A patent/TN2014000520A1/fr unknown
- 2014-12-16 CR CR20140581A patent/CR20140581A/es unknown
- 2014-12-17 ZA ZA2014/09291A patent/ZA201409291B/en unknown
- 2014-12-24 CL CL2014003531A patent/CL2014003531A1/es unknown
- 2014-12-25 IL IL236472A patent/IL236472B/en active IP Right Grant
- 2014-12-26 CO CO14284191A patent/CO7160098A2/es unknown
-
2018
- 2018-07-30 US US16/049,580 patent/US20190160171A1/en not_active Abandoned
-
2019
- 2019-11-22 US US16/692,487 patent/US20200085958A1/en not_active Abandoned
-
2020
- 2020-09-18 US US17/025,826 patent/US20210008216A1/en not_active Abandoned
-
2022
- 2022-05-19 US US17/748,464 patent/US20220354956A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37809B1 (fr) | Administration de médicament biodégradable pour compositions hydrophobes | |
| MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
| BR112013016662A2 (pt) | composições biodegradáveis para administração de fármaco | |
| MA39094B1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| WO2011014850A3 (fr) | Formulations à usage topique à base d'un eutectique | |
| HK1216319A1 (zh) | 无水的水凝胶组合物 | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| EA201370006A1 (ru) | Местная фармацевтическая композиция, содержащая флурбипрофен | |
| MX2010005013A (es) | Composiciones intranasales. | |
| UA102120C2 (ru) | Пероральная форма дозирования бендамустина | |
| MA34670B1 (fr) | Inhibiteurs de l'apoptose et leurs utilisations | |
| FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
| MX2021013488A (es) | Formulaciones liquidas de dosis oral de metilnaltrexona. | |
| MA20150235A1 (fr) | Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne | |
| EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
| WO2008027340A3 (fr) | Formulations ophtalmiques locales | |
| MA46266B1 (fr) | Formes cristallines | |
| WO2012147101A3 (fr) | Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci | |
| TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
| WO2016014680A3 (fr) | Compositions transmucosales orales comprenant des inhibiteurs d'aromatase pour lutter contre les faibles taux de testostérone chez les hommes | |
| MA20150424A1 (fr) | Compositions liquides orales pédiatriques contenant du nepadutant | |
| ECSP11010752A (es) | Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides | |
| UA102010C2 (ru) | Комбинация активных ингредиентов, которая содержит нестероидное противовоспалительное лекарственное средство и производное колхикозида | |
| WO2011128914A3 (fr) | Compositions pharmaceutiques de pramipexole à libération prolongée | |
| FR3058060B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. |